Our Approach
Focused on making today better for people living with rare disease.
We are a fully integrated rare disease business team focused on bringing innovations through to families and patients in need of therapeutic options. We are built to move quickly — advancing treatments efficiently, responsibly, and with respect for the people who need them most.
There is no single playbook in rare disease. Every community is different. That’s why our approach is tailored, not templated. We combine end-to-end execution with close listening to learn directly from advocates, researchers, clinicians, patients, and families. By understanding each community on its own terms, we are better able to remove barriers and ensure community members are well informed to make decisions.
This is one organization that I would say is definitely patient-driven. We are always trying to understand more about what the patient is going through. Everything we’re doing is all about the patient. And I love that.”
A history of results.
A culture of impact.
As the United States rare disease affiliate of Italfarmaco, an established global pharmaceutical company, we combine a flexible, entrepreneurial approach with a longstanding record of delivering meaningful results.
Global Legacy
Our parent company is a private, global company with a long history of developing innovative medicines used by patients around the world. Founded in 1938 in Milan, Italy, Italfarmaco now operates in more than 90 countries across five continents, advancing research to address unmet medical needs across a broad range of therapeutic areas.
Italfarmaco's Reach
90+
Countries
Across 5 Continents
3,800
Group Employees
80+
Year in Business
100%
Family Ownership
4
Research & Development Hubs
Italy (2) + Spain (2)
6
Manufacturing Sites
Milan, Frosinone, Madrid, Barcelona,
Salvador de Bahia + Santiago de Chile
300+
Research + Development
Employees
Entrepreneurial Drive
ITF Therapeutics was established in January 2024 with headquarters in Concord, MA to develop and commercialize rare disease treatments in the United States. Within six months of the company’s launch, we secured FDA approval for our first product and made it commercially available. By our first anniversary, we had reached well over a thousand patients in the US with commercial supply. As our impact grows, we maintain close partnerships with the patient, physician, and payer communities and remain flexible and nimble so our work can be continuously informed by their perspectives.